ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML Post author:admERY Post published:January 15, 2014 Post category:Newsroom ERYTECH announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain. You Might Also Like ERYTECH to Present at the 2018 BIO CEO & Investor Conference February 8, 2018 ERYTECH’S COMBINED SHAREHOLDERS’ MEETING May 26, 2020 ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI January 24, 2022
ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI January 24, 2022